Cipla’s US recovery, biosimilar pipeline key to future growth prospects

What happened: Cipla's US recovery and biosimilar pipeline are cited as key to its future growth prospects, while India remains its biggest growth engine with double-digit growth. Key numbers: Ebitda margin fell 630 basis points year-on-year to 18.7%, up 200 basis points sequentially. FY27 Ebitda margin guidance retained at 18.5%-20%. Why it matters: Margin improvement is expected in the second half of FY27 on respiratory launches and product mix, but the stock may stay range-bound until revenue and profit recovery is clear.

Cipla's US recovery and biosimilar pipeline drive future growth prospects.

Cipla's US recovery and biosimilar pipeline drive future growth prospects. — impact context not separately stored; see What changed.